Investor Presentation • Jun 3, 2021
Investor Presentation
Open in ViewerOpens in native device viewer
June 3, 2021
This document has been prepared by GRIFOLS, S.A. (GRIFOLS or the "Company") exclusively for use during the 2021 Investor and Analyst Day on June 3, 2021. Therefore it cannot be disclosed or made public by any person or entity with an aim other than the one expressed above, without the prior written consent of the Company. The Company does not assume any liability for the content of this document if used for different purposes thereof. The information and any opinions or statements made in this document have neither been verified by independent third parties nor audited; therefore no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Neither the Company, its subsidiaries nor any entity within the GRIFOLS group or any subsidiaries, the company's advisors or representatives assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement.
This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law (Royal Legislative Decree 4/2015, of 23 October, as amended and restated from time to time), Royal Decree 1310/2005, of November 4, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction.
This document contains forward-looking information and statements about GRIFOLS based on current assumptions and forecast made by GRIFOLS management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forwardlooking statements are statements that are not historical facts and are generally identified by the words "expected", "potential", "estimates" and similar expressions.
Although GRIFOLS believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update these forward-looking statements or conform them to future events or developments. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of GRIFOLS.
Investor & Analyst Day June 21
- 4 -
Overcoming adversity and adapting to change
2020
Expressing our gratitude to our 24,000 employees for their commitment and dedication
Strengthening our commitment to patients by ensuring continuous delivery of their treatments
Recognizing more than ever the generosity of donors for their ongoing contribution toward enhancing people's health and well-being
Driving our expansion plan and helping countries achieve plasma self-sufficiency
Accelerating our efforts to innovate
A Global Model of Sustainable Plasma
Only 29% of countries obtain their hemoderivatives through nationally collected plasma (WHO)
Since 2010 global plasma collections are growing but U.S. dependency has also been increasing (MRB)
In 2019, 68% of total plasma collected comes from U.S. (from the 57% in 2010) (MRB)
In Europe, self-sufficiency levels short fall by 40% (1)
First Scientific Journal Dedicated to Plasma Science
Plasmatology aspires to become a scientific point of reference in the field of plasma science
It gathers all research, from basic research to clinical application
- 8 -
Efforts to Secure Plasma Supply and Promote Our Innovation Strategy
Global Century-Old Company Built On Strong Values and Ethical Principles
Reinforcing Our Governance and Sustainability Strategy
… to continue driving our sustainability strategy
Integrated in our corporate strategy
Investor & Analyst Day June 21
- 12 -
Investor & Analyst Day June 21
- 13 -
Strengthening a global plasma-center network to ensure plasma supply and promote long-term sustainable growth
Multilevel Strategy to Increase Plasma Supply
Analyst Day June 21
Solid Rebound in Germany. Steady Recovery in U.S. Since April
2021 Investor & Analyst Day June 21
Analyst Day June 21 Strengthening Grifols' Plasma-Center Network
Diversification Plasma Center Capacity Business Optimization
Advancing the Execution of the Expansion Plan
Expanding and Diversifying Grifols' Presence
Diversification Plasma Center
Business Optimization
Capacity
Expanding and Diversifying Grifols' Presence
Diversification Plasma Center
Business Optimization
Capacity
Capacity Business Optimization
Expanding and Diversifying Grifols' Presence
Grifols continues to expand and diversify its U.S. based plasma-center network
Leveraging mature and licensed centers leads to an immediate increase in plasma supply
Through these acquisitions, Grifols broadens its footprint to new states and regions
Grifols continues to expand and diversify its access to European plasma adding plasma centers from Hungary
This transaction strengthens Grifols' leadership in Europe in terms of geographic scope and use of EU-approved plasma
Diversification Plasma Center Capacity Business Optimization
| Plasma Centers |
CHINA | SRAAS |
|---|---|---|
| Operating | 270 (1) |
38 (3) |
| Under Construction | 20 (2) |
3 |
| Total | 290 | 41 |
Access to new sources of plasma to reduce dependency on U.S. plasma
| Source: Reports released by manufacturers. Updated on Apr. 26, 2021 | |
|---|---|
| (1)Includes 26 branch centers; (2) includes 2 branch centers; (3) includes 1 branch center |
June 21
Diversification Supports Business Continuity
450 Plasma Centers1 Grifols Global Presence by 2022 Strategy
USA EU China Egypt
Analyst Day
- 23 -
Digital Transformation
Investor & Analyst Day June 21
Integrated Technology to Enhance Donor Experience
Information from nearly 1 million active donors
Plasma-center personnel engage with donors
in Donor Hub
to donors
+13 million emails
Over 220K donors registered
Grifolsplasma.com
Automated marketing campaigns and multiple digital and tech tools
+100k text messages and push notifications sent
Business Optimization
• More new donors
Capacity
Analyst Day June 21
Capacity
Significant reduction test turn-around times (~48 hrs)
Academy continues to deliver virtual programs during Covid-19
Analyst Day June 21 Leveraging Technology to Optimize Efficiencies Diversification Plasma Center
Digital Transformation
Capacity
Business Optimization
Manages donor center activities such as donor and unit suitability and shipments
Establish optimal levels of commitment compensation based on analytics and market environment
- 26 -
Analyst Day June 21
Expected Improvements Derived From Business Optimization
Capacity
Business Optimization
- 27 -
Analyst Day June 21
Capacity Optimization
Business
Donor commitment compensation increased in 2020 to recognize donor loyalty, COVID-19 challenges and better compete in the current plasma market
Compensation increase does not imply the same increase on total cost due to the weight of different drivers
Donor Commitment Compensation Other Operating Costs
Investor & Analyst Day June 21
- 29 -
Analyst Day June 21
Thanks to strong inventory management policies, Grifols was able to build a significant stockpile of the main 4 proteins and plasma over the last 4 years and partially offset the 2020 impact
This position ensures product delivery by enabling an agile response to market variability and uncertainties
Operations Supports Product Delivery
This trend is evidence of the robust inventory management in place
Packaging vials per year has increased since 2017
Analyst Day June 21
Analyst Day June 21
- 32 -
▪ Supply chain improvement through coordination and automation of the process
▪ Electronic batch record with workflow enforcement, electronic workflow for approval of batch documentation (paperless)
▪ Capture information across the whole site, real-time visibility across production lines
▪ Virtual reality to support industrial processes including training and virtual tours
▪ Application of AI-based behavioral models and supercomputing designs to increase yield in all steps of downstream
Grifols continues to reinforce its global plasma-center network to secure plasma supply and support long-term sustainable growth
Grifols advances the execution of its plasma expansion and plan through diversified organic and inorganic growth, as well as optimized efficiencies
Business optimization thanks to technology enhancements including digitalization and a fully integrated supply chain
Innovation-led improvements will drive growth of plasma supply
Robust inventory management has ensured essential product deliveries and greater efficiencies
Solid recovery expected throughout 2021
Investor & Analyst Day June 21
Albert Grífols Coma-Cros – Chief Scientific Innovation Officer Karoly Nikolich – Alkahest's CEO José Terencio – VP Innovation Joana Sàbat – VP Bioscience Global Marketing Antonio Martínez – President Diagnostic Scientific & R&D
- 35 -
Investor & Analyst Day June 21
1
- 36 -
- 37 -
Setting Three Large Hubs
12
last 3 years
A Pioneering Ecosystem to Promote Knowledge and New Opportunities
- 38 -
Integrating Internal and External Innovation
Vicente Blanquer VP R&D & Regulatory affairs
Karoly Nikolich CEO Alkahest
José Terencio VP Innovation, Grifols Innovation and New Technologies (GIANT)
Eva Bastida VP Scientific & Medical Affairs
Matt Murawski VP Bioscience/ Diagnostic Scientific Development
Séamus McCooey Director Global Intellectual Property
Investor & Analyst Day June 21
Sizable, Diversified, Steady Revenue Contribution
Investor & Analyst Day June 21
- 42 -
Delivering A Comprehensive Pipeline to Support Our Patients
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Phase 4 / Regulatory |
LCM | |
|---|---|---|---|---|---|---|---|
| Immunology | 2 GRI programs 1 GIGA program |
rSCIG Spike in PdIG with enriched libraries (PID) |
SCIG/IVIG SIDs-CLL |
IVIG-PEG | Xembify® Europe Xembify® Bi-weekly dose |
Xembify® Prefilled syringes |
|
| Hepatology | 2 GRI programs | Albumin 20% ACLF (APACHE) Albumin 5% Decompensated Cirrhosis (PRECIOSA) |
FlexBag® US FlexBag® EUR |
||||
| Pulmonology | Alpha-1 AT Non-cystic fibrosis bronchiectasis |
Alpha-1 AT 15% (SC) AAT deficiency |
Prolastin-C® EUR (SPARTA) |
Prolastin® EU 4-5gr vials |
|||
| Haematology | 2 GRI programs | ATIII New indication Fibrinogen Acquired Deficiency |
Fostamatinib*** AIHA indication Fibrinogen Congenital Deficiency and severe hypofibrinogen |
||||
| Ophthalmology / Others |
6 GRI programs 3 ALK programs 2 GIGA programs |
GIGA 564 Anti-CTLA-4 Oncology |
AKST4290 & DR |
Fibrin Sealant Biosurgery pediatric Use |
|||
| Infectious Diseases |
4 GRI programs 2 GIGA programs |
IgM Bacteremia HIV Antibody HIV** GIGA 2070 COVID-19 |
GIGA 2050 COVID-19 |
||||
| Neurology | 3 GRI programs 5 ALK programs |
GRF6019 ABvac40 AD AD GRF6021 AKST4290 PD with PD Dementia |
* Alkahest; ** Project of AlbaJuna (Grifols' invested company); *** Licensed rights from Rigel Pharmaceuticals in EU and other countries
Commercial R&D
- 43 -
Investor & Analyst Day June 21
- 44 -
Increasing Incidence of Dementia
Dementia involves loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with daily life
"One of the major challenges of our generation"
We are facing a global challenge to find a cure, improve treatment, and ensure enough resources to enable people to live well with dementia
Sources: Alzheimer's Disease International, Worlds Alzheimer Report 2015, https://www.alz.org/alzheimers-dementia/what-is-dementia
Sources: Parkinson Foundation; Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010 Feb 15;289(1-2):18-22. doi: 10.1016/j.jns.2009.08.034. Epub 2009 Sep 4. PMID: 19733364
- 47 -
Investor & Analyst Day June 21
Our Innovation Strategy in Neurogenerative Diseases (ND)
| Strategy Focus | |
|---|---|
| Diseases | Understanding the molecular basis of ND and those related with aging |
| Mechanism of Action (MoA) |
Disease-modifying therapies vs. Treating symptoms |
| Products | Antibody, small molecules, RNA-based drugs, plasma-derived drugs, etc… to be developed according to the validated therapeutic target |
Our Innovation Strategy in Neurogenerative Diseases (ND)
- 49 -
- 50 -
The Language of this Communication Encodes Health and Disease
Day June 21
We Are "Molecularizing" Plasma
7597 proteoforms
Decoding Causal Relations of Disease Processes
Best-in-class Plasma Proteomics
Proteomics Lead the Way to Disease Mechanisms
Most extensive profiling (>10,000 proteins) of healthy aging and diseases
Mass spectrometry, multiple array technologies
Plasma Fractions & Small Molecules
Differentiation between multiple diseases states (>60)
Increased interpretability of diseases by clustering
- 55 -
Novel Therapeutic Candidates From Plasma
Results Cognitive functions improved Statistically meaningful differences between Plasma Fraction and Placebo Safety and tolerability of dosing paradigm favorable Effect size superior as compared with currently used cognitive enhancer agents
Analyst Day June 21
- 56 -
1 Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther. 2010;16(6):330-336. doi:10.1111/j.1755-5949.2010.00182.x; 2Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012 Sep 1;27(10):1230-8. doi: 10.1002/mds.25098. Epub 2012 Aug 22. PMID: 22915447
Functional Improvements in Cognition and Daily Activities
- 57 -
- 59 -
Investor & Analyst Day June 21
- 60 -
- 61 -
1 MRB 2018: Analysis of Ig market in the U.S. 2018 and Forecast to 2025: 2Bousfiha et al. Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought. J Clin Immunol. 2013; 33:1-7; 3Internal Estimate ; 4Chronic Lymphocytic Leukemia
CLL is the Fastest Growing Patient Segment for IG Therapy
HGG1 occurs in up to 85% of patients with CLL (due to malignancy itself and/or treatment)2,3
>60%mortality Associated with a high rate of infections that account for
Program to include both IVIG and SCIG for CLL SID U.S. indication. Unique for SCIG
Opportunity to add clinical evidence to differentiate IG portfolio in markets with approved SID indications
Expected launch: 2026
1 Hypogammaglobulinemia; 2Friman V et al. Hematol Oncol. 2016;1-12: doi 10.1002/hon.2323 [Epub ahead of print]; 3Seppänen M. Clin Exp Immunol. 2014;178(Suppl 1):10-13; 4Internal data
Analyst Day June 21
U.S. Leukemia Prevalence
Reduces medical supply waste
Adds flexibility with new dosing regimen option
Offering broader administration options provides a greater opportunity for treatment satisfaction and patient empowerment, which may support high levels of patient compliance
Analyst Day June 21
Smart Pump System
Improving IVIG & SCIG home infusion treatment experience
Simplify the infusion process, improve ease of use, and add mobility/freedom
Bluetooth connectivity to an app/dashboard
Superior features over disposable wearable devices
Opportunity to leverage digital health platform to improve patient outcomes
- 65 -
Investor & Analyst Day June 21
- 66 -
Our Cirrhosis Management Perspective
- 67 -
Our Innovation Strategy in Hepatology
| Albumin Most abundant protein in the body |
||
|---|---|---|
| Focus of investigation 15 years for more than Clinical & non-clinical program to understand Albumin's role in health and disease MoA and |
Albumin is widely used as a volume replacement/ expander fluid as a volume |
Albumin is shown to be altered in disease2,3 |
| these investigations… Concept of albumin as a pharmaceutical |
replacement/ expander fluid1 |
|
| with a multifactorial Mechanism of Action (focusing in hepatology and other |
Albumin infusion shows clinical improvement in decompensated cirrhosis4 Plasma Protein Replacement with albumin may provide benefits across different diseases5,6
Investigations into albumin's potential use as a drug in complex diseases are underway
(focusing in hepatology and other diseases like Alzheimer)
- 68 -
1 Vincent JL et al. Crit Care. 2014;18(4):231; 2 Garcia-Martinez R et al. Hepatology. 2013;58(5):1836-46; 3 Costa M et al. J Alzheimers Dis. 2018;63(4):1395-404; 4 Caraceni P et al. Lancet. 2018; 5 Boada M et al. Alzheimers Dement (N Y). 2019;5:61-9; 6 Laleman W et al. Can J Gastroenterol Hepatol. 2018;2018:1027152
More Than Just a Volume Expander
Its Function Correlates With Clinical Outcomes in Advanced Cirrhosis
- 71 -
Prevention of Mortality in Subjects With Decompensated Cirrhosis and Ascites
U.S., Canada, Belgium, Denmark, France, Germany, Italy,
Spain and UK
- 72 -
Investor & Analyst Day June 21
ALADDIN Study: Understanding Disease Pathogenesis and PE-A 5% MoA
Effects of Plasma Protein Replacement with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality
Translational research project supporting Apache, aim to provide key insights on ACLF and Albumin MoA
failure and ACLF in cirrhosis
PE A-5% mechanism of action in ACLF
Ph3, 1:1 randomized, multicenter, open label enrolling 380 ACLF subjects (90 days FU): SMT vs SMT + PE A-5% 40 centers from US and 8 EU countries
• Est. study end (LPLV): 2Q 2022 • Recruitment update: 109
subjects randomized (29%)
N = 250 patients from EU participating in APACHE (59 randomized (24%), April 2021)
Long-Term Albumin Use
- 74 -
Investor & Analyst Day June 21
| GRIFOLS | ||
|---|---|---|
- 75 -
Analyst Day June 21
Permanent Threat of Emerging Pathogens Calls for Developing New Therapies
Issue of global concern as incidence has increased dramatically in recent years
Transmission and spread at an unprecedented speed influenced by human-related factors1
| Globalization | |
|---|---|
| Climate change | |
| Human-wild animal interface | |
| Antimicrobial resistance | |
| Host susceptibility | |
| Behavior changes |
Deaths
The number of deaths from outbreaks recorded in the last two decades shows the big impact of infectious disease
- 76 -
1Journal of Physiological Anthropology volume 39, Article number: 29 (2020); 2https://www.who.int/csr/sars/country/2003_07_11/en/; 3The Lancet Infectious Diseases, 12(9), 687-695. doi:10.1016/S1473-3099(12)70121-4; 4 https://www.ecdc.europa.eu/en/middle-east-respiratorysyndrome-coronavirus-mers-cov-situation-update; 5https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html; 6https://apps.who.int/iris/bitstream/handle/10665/204348/zikasitrep_5Feb2016_eng.pdf;jsessionid=2E8C110C039D151C1EE6B384A9F064A8?sequence=1; 7WHO
- 77 -
10% Hyperimmune globulin IV
Study to evaluate its Safety and Efficacy in nonhospitalized patients with COVID-19
20% Hyperimmune globulin SC
Study to evaluate the safety and efficacy in infected asymptomatic ambulatory outpatients
Non-hospitalized patients age ≥ 55 with COVID-19 who have had COVID-19 symptoms ≤ 5 days
Target population
Ambulatory Asymptomatic patients with confirmed SARS-CoV-2 infection
Platform built from our vast experience in developing immunoglobulins from selected donors against specific pathogens
- 79 -
2021
Analyst Day June 21
Day
12,000 Anti-Coronavirus Antibodies Captured From 16 Convalescent Donors
June 21
Manufacture as a recombinant monoclonal antibody (rMAB), regulatory framework generally followed standard rMAB
Acute monkey toxicity study showed no drug-related events at the highest dose tested (475 mg drug / kg body weight)
Sorting for binders to SARS-CoV-2 RBD, and removing antibodies that don't bind, reduces diversity but enriches neutralizing titer
Day June 21
Commitment With Society and the World, Preparing for Future Challenges
as vaccination progresses number of COVID-19 new cases is expected to be significantly reduced
in developed economies with massive access to vaccines
Vaccination is still well below
herd immunity targets
(25% of US population won't be vaccinated* )
Grifols is committed to society to keep working to bring new therapies
Not all countries have broad access to vaccines
COVID-19 is devastating in countries like India
that might become resistant to vaccines
Investor & Analyst Day June 21
- 82 -
2021 Investor & Analyst Day
Potent CCR3 Inhibitor for Multiple Therapeutic Indications
Addressing AMD and Diabetic Retinopathy
Membrane Permeability/Degradation
Immune Cell Recruitment
Cytokine Upregulation
Heightened Neuroinflammation & Neurodegeneration
2021 Investor & Analyst
Day June 21
New Insights Into the Pathology of Eye Diseases: Cytokines and Immune Cells
Inflammatory Proteins from Circulating Plasma Accumulate in the Eye
AKST4290 Reduces Inflammatory Proteins and Infiltrating Immune Cells in the Eye
2020
| Naïve patients (201) | Mean (Median) | N (%) |
|---|---|---|
| Overall BCVA Gain | +7.0 (8) | 29 (100%) |
| "Responders" ≥5 Letter BCVA Gain |
+14.9 (11.5) | 16 (55%) |
| ≥10 Letter BCVA Gain | +17.3 (15.5) | 12 (41%) |
| ≥15 Letter BCVA Gain | +23.2 (22) | 6 (21%) |
| RPE-DH Change | -79.3 (31) | 19 (66%)* |
| CST Change | -13.9 (-4) | 29 (100%) |
* 19 of 29 subjects with RPE Detachment
Strong improvement in Best Corrected Visual Acuity: similar to standard of care aVEGF1 injections into the eye
Oral agent a substantial advancement compared to the high treatment burden of current intravitreal aVEGF
1 Vascular Endothelial Growth Factor
- 87 -
Manifestations of DR Characteristics and Progression of DR
Investor & Analyst Day June 21
- 90 -
Analyst Day June 21 Diagnostics R&D Areas of Focus
Proteins
DG Gel
New Antisera development
New gel card DG Gel DC Scan Plus testing
Extended phenotyping
Kit to resolve daratumumab interference for cancer patients
Discriminatory Multiplex: HIV/HCV, HBsAg
| HBcore | Chagas | HTLV |
|---|---|---|
| Syphilis | CMV | HBsAg |
| Confirmatory |
Promonitor Quick Anti-IFX & IFX
Promonitor Quick Anti-ADL & ADL
| Screening/Diagnostics | Therapeutics |
|---|---|
| • IAs for Donor Screening • Immunohematology |
• Alkahest (Neurodegeneration) • Biosciences (SARS CoV2) |
| CDMO Opportunities (external customers) |
Investor & Analyst Day June 21
Recombinant Protein Excellence in Microbial and Mammalian Systems
Combining the Chiron legacy of recombinant expression innovation with Grifols quality and excellence
Orphan drugs
Vaccines
Wound healing
Therapeutic enzymes
Analyst Day June 21 Diagnostics R&D Areas of Focus
Nucleic Acids
- 93 -
NAT Donor Screening
Panther ART: to support greater lab automation and efficiency
Improved middleware
Other New Procleix® Assays
Babesia assay: CE Marked (Jan 2021)
Plasmodium assay: in development
New Multiplex Procleix® Assays
UltrioPlex® E assay
ArboPlex® assay
New Solutions to Enhance Testing Efficiency and Blood Safety
Procleix® UltrioPlex E assay: results for 5 viruses into single reaction: HIV-1, HIV-2, HCV, HBV, and HEV
Procleix® ArboPlex Assay: results for 5 arthropod-borne viruses (or "arboviruses") into a single reaction: West Nile, Usutu, chikungunya, dengue, and Zika viruses
Other multiplex assay concepts in feasibility
Increases laboratory efficiency:
Increases production efficiency by combining manufacturing operations
and liquid waste)
Analyst Day June 21 Diagnostics R&D Areas of Focus
Nucleic Acids
NAT Donor Screening
Lab Automation
Panther ART: to support greater lab automation and efficiency
Improved middleware
Other New Procleix® Assays
Babesia assay: CE Marked (Jan 2021)
Plasmodium assay: in development
New Multiplex Procleix® Assays
Ultrio® Plex E assay
ArboPlex® assay
Procleix® SARS-CoV-2 assay
Procleix® SARS-CoV-2 Assay Developed in <3 Months
CE marked: May 2020
Assay runs on fully automated Procleix® Panther system
Among most sensitive EUA NATs according to results from testing FDA SARS-CoV-2 Reference Panel
Our ultra-high sensitivity and long experience in donors testing allows testing in pools of samples improving efficiency
Over 10 million tests manufactured in San Diego
EU1 : as an aid in diagnosis of COVID-19 (respiratory specimen testing)
US: organ/tissue donor screening to support transplant safety
Grifols' employee testing
SARS-CoV-2
Procleix ® Panther System
- 97 -
Analyst Day June 21 Diagnostics R&D Areas of Focus
Nucleic Acids
NAT Donor Screening
Lab Automation
Panther ART: to support greater lab automation and efficiency
Improved middleware
Other New Procleix® Assays
Babesia assay: CE Marked (Jan 2021)
Plasmodium assay: in development
New Multiplex Procleix® Assays
UltrioPlex® E assay
ArboPlex® assay
Infectious Diseases
Procleix® SARS-CoV-2 assay
Development of GRIFOLS Genetic Service for A1AT Deficiency testing, direct to patients (Over-The-Counter)
AlphaID™ At Home Genetic Health Risk Service Website
AlphaID™ At Home Saliva Collection Kit
A1AT Genotyping Test for OTC
Genetic Health Risk Service Result Report
Order online AlphaID™ at Home
Use AlphaID™ At Home Saliva Collection Kit at home
Ship saliva collection device with collected sample to lab
Access report online via secure patient portal
Over-the-Counter (OTC) Innovative Solution to expand the U.S. screening program
The OTC At Home Service is in the design and development stage
Day June 21
Accelerate Diagnosis to Stop Genetic Emphysema's Progression
Grifols WW Testing Program
>850,000 tests performed
Investor & Analyst Day June 21
Self-Testing Will Provide Benefits for Patients and HCPs
Allows for further developments that would accelerate testing by better addressing customers needs
Analyst Day June 21
- 103 -
| Product | Indication | Market Size | |
|---|---|---|---|
| Immunology | SCIG / IVIG | SIDs-CLL | |
| ACLF | |||
| Hepatology | Albumin | LTA Cirrhosis | |
| Pulmonology | Alpha-1 AT | Non-CF Bronchiectasis | |
| Fostamatinib | AIHA | ||
| Haematology | Fibrinogen | Acquired Deficiency | |
| ATIII | New indication | (each) | |
| HIV Antibody | HIV | ||
| Ophthalmology / Others |
AKST4290 | nAMD & DR | |
| GIGA 564 | Anti-CTLA-4 Oncology | (each) | |
| Infectious | IgM | Bacteremia | |
| Diseases | GIGA2050 | COVID-19 | |
| GRF6019 | Alzheimer's Disease | ||
| AKST4290 | Parkinson's Disease with Dementia | ||
| Neurology | ABvac40 | Alzheimer's' Disease | (each) |
| GRF6021 | Parkinson's Disease |
| New leadership and governance |
|---|
| to effectively foster and support |
| breakthrough innovation |
Executing on our Innovation Strategy within and outside the plasma space to achieve a more risk-value balanced portfolio
Focus on high prevalence and transformational therapies that meet global challenges with huge untapped potential
Transforming disease management in Neurology, Ophthalmology and Infectious Diseases through innovative platforms led by Alkahest and GigaGen
Exploring large opportunities on plasma: sharpen focus on CLL; shaping cirrhosis treatments and accelerating alpha-1 diagnostic
Strengthening pipeline in Diagnostic across the value chain and new diseases
Investor & Analyst Day June 21
Lafmin Morgan – Chief Commercial Officer
- 105 -
June 21
Short-Term Impacts Continue in 2021, but Receding
| Patients | Healthcare Hospitals & Providers Institutions |
Commercial Interactions |
||
|---|---|---|---|---|
| Diagnosis visits remain 12% below 2019 baseline, generating a -3,8% gap in Px1 |
Biopharma in-person patient visits were up 17% in March'21 with all specialties increasing1 |
Lab testing (all settings) still below 20192 |
Perceived value of 1-1 VC vs. in-person has fallen; both Specialists and PCPs now |
|
| Elective procedures still | The pandemic could cause | want more in-person1 | ||
| remain 15% below 2019 levels1 |
Total prescriptions recovering compared with 2020 (+6%)1 |
U.S. hospitals to face between \$53 billion and \$122 billion in revenue loss this year3 |
Total Biopharma details increased 13% in March'21 rising to 93% of baseline1 |
Sources: 1 IQVIA data published April 2021; 2 IQVIA data published September 2020; 3Hospital finances in 2021: 10 things to know (www.beckerhospitalsreview.com)
June 21
Patients Are Facing Additional Challenges
Providing Support, Bringing New Therapies and Looking for New Solutions
| Alpha-1 patients | PID/SID patients | ITP patients | COVID-19 patients |
|---|---|---|---|
| Patient Support Programs (US, EU and LATAM) |
Xembify® launch in the US |
Launch of Tavlesse® just after COVID-19 wave 1 |
Development and launch of TMA in <3 months |
| Home Infusion | Continuous support to patients groups |
R&D of therapies to fight against COVID-19 |
|
| AlphaIDTM in patient hands |
Increasing Our Revenues in This Extraordinary Context
- 109 -
Investor & Analyst Day June 21
• New flexible container to complement vials and broaden Grifols offering to customers
• US launch in 2021
Investor & Analyst Day June 21
- 111 -
Revenues Reach EUR 4,241M With a 8% CAGR
Investor & Analyst Day June 21
- 113 -
Accelerate Diagnosis and Stopping Genetic Emphysema's Progression
is helping to accelerate diagnosis and is the base for innovative testing strategies
>850,000 tests performed
- 114 -
Analyst Day June 21
NIH Estimates 500,000 Undiagnosed PIDD Patients in the US1
DIAGNOSIS
Average PIDD diagnosis still takes 12.4 years2
- 115 -
Grifols is uniquely positioned to leverage our expertise in IG replacement therapy and diagnostics to improve the rate and time to an appropriate PIDD diagnosis
1 Modell V. Immunol Res. 2007;38(1-3):43-47; 2 . Routes J, et al. J Clin Immunol. 2016;36:450-461. 3Boyle JM, Buckley RH. J Clin Immunol. 2007;27(5):497-502; 4 French MA, Tangye SG. J Infect Dis. 2019;jiz230. doi:10.1093/infdis/jiz230; 5Bonilla FA, et al. J Allergy Clin Immunol. 2015;136(5):1186-1205.e1-78
Investor & Analyst Day June 21
- 116 -
Significant Room to Continue Helping Patients with SIDs
NEW USES AND INDICATIONS
Driven by…
Increased use of SID-inducing medication in both oncological and autoimmune indications
Extended survival rates of cancer patients
1 US PPTA Distribution Data;; 2 Friman V et al. Hematol Oncol. 2016;1-12: doi 10.1002/hon.2323. [Epub ahead of print]; 3 Seppänen M. Clin Exp Immunol. 2014;178(Suppl 1):10-13. SID: Secondary Immune Deficiency (not an FDA approved indication in the U.S.)
The Use of Albumin in Liver Disease Will Become a Key Growth Driver
NEW USES AND INDICATIONS
- 117 -
Investor & Analyst Day June 21
IgG per Capita Consumption Growth in the Coming Years
Raising awareness on PIDD diagnosis and treatment
Growing uses and indications in SIDs
2013-2020 per capita consumption (g/000 Population) for top markets worldwide
Aiming to Meet the Large, Unmet Medical Need in PIDD
Xembify® U.S. Sales Volume Since Launch
Xembify® sees growth in Q1 2021 through an accelerated base of patients and prescribers, paving the way for continuity and further adoption in 2021
of Xembify® prescribers continue to prescribe Prescribers Dec 2020 Mar 2021 90% Patients of Xembify® patients that 85%
Mar 2021
start, continue treatment
Dec 2020
Investor & Analyst Day June 21
Continue to Bring New Therapies for Chronic ITP Patients*
Tavlesse® GER Sales Volume since Launch
Tavlesse® has been successfully launched in Q3 2020 in UK and Germany
Investor & Analyst Day June 21
- 121 -
Delivering on Our Promises
In the face of increasingly tough competition (SCIG products) years ago we committed to keep outperforming
Xembify® launch and customer centric developments will allow us to keep strengthening our market position
the IVIG market and even considering the IVIG + SCIG market
CAGRs
- 122 -
A strong customer centric mindset has permitted Grifols to improve market share in the middle of the global pandemic
| Reliable Supply | Patient Support | Testing Continued Innovation |
|---|---|---|
| ----------------- | ----------------- | --------------------------------- |
Important Alpha-1 product shortage from competitor in Q4'20 - Q1'21 challenged treatment continuity of hundreds of patients in EU during pandemic
Grifols, the Global Alpha-1 leader, was ready to immediately put in place all efforts thus guaranteeing therapy to patients
A strong customer centric mindset has permitted Grifols to improve market share in the middle of the global pandemic
A strong customer centric mindset has permitted Grifols to improve market share in the middle of the global pandemic
Investor & Analyst Day June 21
&
Investor & Analyst Day June 21
- 127 -
Sustainable Growth Over the Last 5 Years
- 128 -
Plasma Testing Poised for Strong Growth
donations tested every minute with a Procleix® assay*
We are converting all Grifols testing locations to Procleix® Instruments and Assays
Recent plasma center
Our Innovation Strategy Delivering on the Future Needs of Transfusion Patients
Making an Impact in Blood Banks Operation
Hepatitis E virus (HEV) is one of the leading causes of acute viral hepatitis worldwide
HEV-RNA screening of blood donations implemented in eight EU countries
Incidence of HEV infection in Europe over 10 years has grown by ten times
- 131 -
HEV INFECTIONS 20M WORLDWIDE
Strong Resilience in Spite of a Global Pandemic
Continuous Success Across All Customer Segments With Highest Customer Loyalty
Investor & Analyst Day June 21
- 134 -
Investor & Analyst Day June 21
COVID-19 Challenges Impacted Performance With a Few Important Exceptions
Hospitals have been significantly impacted by COVID-19 driving decline in Hospital Division revenues in 2020
Pharmatech business was impacted with complex projects being delayed. As a result, Pharmatech revenue declined 11.8% in 2020 after two consecutive years of strong double digit growth
Day June 21
We remain a leader for IV Fluids in Iberia, helping to ensure hospitalized patients receive needed sterile IV solutions
Grifols rapidly implemented medication control technology in new treatment centers deployed during the outbreak in Spain
In the U.S., 93,000 compounded sterile preparations are made every day with the help of PharmacyKeeper
When significant logistical challenges arose for distributing vaccines within hospitals PharmacyKeeper enhanced its industry award winning* IVWF software, to help optimize dispensing for patients
Investor & Analyst Day June 21
- 137 -
Successful Business Expansion Over the Last 4 Years
- 138 -
Building the Pillars to Assure Excellence in Long-Term Partnerships
Biopharma Diagnostic
Provide additional value to Grifols proteins in niche markets
Vertical integration for Diagnostic IH by supplying blood components as raw material while providing additional value to non-suitable for fractionation plasma
2021 Investor & Analyst Day June 21
Several companies using Grifols excipients in clinical trials
New industry applications for current portfolio
New products
| Customer and patient centricity has allowed us to be prepared for the future |
Grifols grew in 2020, with 50% contribution to growth from new products and achieving 40 consecutive quarters growing QoQ |
Long-term trends remain robust for Bioscience |
|---|---|---|
| Demonstrated ability to succeed in competitive markets |
Long-term trends also support growth in Diagnostic and Hospital divisions |
Bio Supplies is a growing high-margin business, significantly contributing to the development of new drugs and products |
Grifols is Uniquely Positioned to Help Patients and HCPs Along All the Way
June 3, 2021
Investor & Analyst Day June 21
Daniel Fleta – Chief Industrial Officer
- 143 -
Investor & Analyst Day June 21
- 144 -
Population (M) Plasma Collections (M L/year) Canada* 0.3 8.8 37.7 U.S. 45.9 138.7 331.0 5.2 46.1 112.8 Egypt - - 100.3 China 8.9 6.2 1,433.8 Liters per 1,000 population Austria, Czechia, Germany, Hungary Rest of Europe 3.9 6.1 634.3
Analyst Day June 21
- 145 -
Sources: "UN World Population Prospects 2019 Data Booklet"; "Plasma Collections 2019" and "MRB 2019 Global Blood & Plasma Collections Report." Calculation from "Protecting Access to Immune Globulins for Canadians: Final Report of the Expert Panel," Health Canada, 2018.
2018 IgG Plasma Usage vs. Plasma Collected (millions of liters)
Source: "Plasma Flows on a Global Level: Impact and Realities in Europe," Matthew Hotchko, PhD, Marketing Research Bureau, GPS Meeting, October 28-30, 2020.
- 146 -
Analyst Day June 21
Worldwide Prevalence*
Ig – Secondary Immunodeficiencies (i.e. Oncology)
Fight emerging virus i.e. Ebola, COVID-19
*Total Prevalence calculations over 5,360,680 World Population >18years – Source UN World Population Prospects 2019_DataBooklet.
1 World Federation of Haemophilia; 2 Grifols patient counts (last update 10MAY2020): assume 50% of patients diagnoses receive treatment based in market knowledge and affiliate input. COPD Prev 10-18%. COPD, Diagnosis 10-50%; 3 Burden of Cirrhosis on Patients and Caregivers, 2020; ; 4 National Institute of Allergy and Infectious Diseases. Primary immune deficiency diseases (PIDDs). niaid.nih.gov/diseases-conditions/primary-immune-deficiency-diseases-PIDDs Accessed June 30, 2020; 5 https:/ww.who.int/news-room/fact-sheets/detail/sepsis
- 147 -
Exceptional Synergies to Unlock the Potential of Strategic Projects
Tech.Transf. & EPCM Capabilities Grifols Engineering
Patients at the Core Safety & Quality Long-term Partner
Local Presence, Global Reach Unique Approach to Geographies
Investor & Analyst Day June 21
- 149 -
Investor & Analyst Day June 21
Grifols Engineering, Industrial and Quality Expertise Offer a Unique Opportunity
Egypt
Improve Egypt's healthcare system
Know-how and technology
Strategic alliance between Grifols and the Egyptian government will help the country attain selfsufficiency of plasmaderived medicines and enable market expansion in the Middle East and Africa
(Africa, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Iraq, Jordan, Lebanon, Syria and Yemen)
Grifols will have total management oversight for the design and construction of facilities, operations, quality and safety to guarantee selfsufficiency of world-class plasma products
June 21
- 152 -
Investor & Analyst Day June 21
Donor center, plasma testing labs, plasma freezers warehouse, Grifols Academy for Plasmapheresis and plasma ops. offices
Medical City Development Plan in New Capital City
- 154 -
Plasma logistics center, labs, vivarium, R&D, common areas, warehouses, utilities and manufacturing plants
- 155 -
Fractionation, purification and fill-and-finish of:
Analyst Day June 21
- 156 -
Day June 21
| Global plasma collections are growing but the U.S. dependency is also increasing |
Higher demand of PDMP due to healthcare systems development, better diagnosis, new indications and clinical trials to treat high-prevalence diseases |
Egypt offers growth potential as a fast-growing and developing nation and leading regional supplier to the Middle East and Africa |
|---|---|---|
| Clear willingness of the Egyptian government to set a legislative framework that promotes the viability and sustainability of this project |
Grifols Industrial through Grifols Engineering is uniquely poised to offer cutting-edge turnkey solutions |
Free up plasma and manufacturing capacity to serve other growing markets |
Investor & Analyst Day June 21
Amarant Martínez – VP China Affairs Office
- 158 -
Limiting Plasma Collections Impact to -2.0% vs. -9.3% of the Industry
2021
Analyst Day June 21
Source: Reports released by listed manufacturers 2020. Internal Analysis.
Leveraging Our Capabilities to Become Leaders in Albumin and IG
- 161 -
1Multinational corporations; 2Market share; Source: Institutes of Food and Drug Control.
From Third-Party Distribution Model to Strategic Partnership With Leading Manufacturer
| Albumin | FVIII |
|---|---|
| IVIG | PCC |
| IMIG | Fibrinogen |
| Hep B IG | Thrombin |
| Tetanus IG | Fibrin Sealant |
| Rabies IG |
Investor & Analyst Day June 21
1 st step: Reorganization of internal operations by shifting from current partners towards integrated commercial model
Phased implementation of NAT solutions at SRAAS facilities (pool of 96)
Portfolio expansion under assessment:
• Ultrio Plex E (HEV, HIV-1, HIV-2, HCV, HBV)
• New DG Gel Cards
- 163 -
To reach highest rate of: AD prevention and treatment awareness rate; services network; elderly cognitive function screening rate
| Centralized Testing |
Successful SRAAS Pilots according to Provincial Health Commission requirements |
Supporting authorities with Grifols' full-range capabilities |
|
|---|---|---|---|
| R&D | SRAAS development of IVIG 10% and SCIG 20% |
||
| Others | Take Innovation Beyond Plasma to China |
||
- 164 -
Sources: Chinese Aging Well Association-Alzheimer Branch; Jian Kang Shi Bao.
| Unparalleled growth potential across divisions |
Excellent performance amid these challenging times |
Continue delivering on execution in the second year of the alliance |
|
|---|---|---|---|
| Robust capabilities and broader portfolio through the integrated Bioscience commercial platform under SRAAS |
Advancing towards a Diagnostic integrated model |
Innovation as a key element within the alliance |
|
Investor & Analyst Day June 21
Joel Abelson – President Bioscience Commercial
- 166 -
Analyst Day June 21
Deep experience in the Canadian market, with more than 30 years as the primary fractionator for Canada's blood operators
Only large-scale domestic manufacturing facility and uniquely positioned for continued growth across full platform of service offerings
Grifols is supporting Canada's path towards selfsufficiency by partnering with Canadian Blood Services to enhance security of supply in a novel proof-ofconcept partnership model
One of the highest IG usage per capita with one of the lowest plasma donation rates
The pandemic heightened the urgency for plasma selfsufficiency/domestic production
- 167 -
Canada's Blood Operators
One of the Highest IG per Capita. One of the Lowest Plasma Donation Rates
Canada is one of the highest users of Ig per capita…
• Canada's plasma volumes sent for fractionation are Liters collected per 1,000 population United States: 113 L Austria: 75 L Czechia: 45 L Germany: 36 L Spain 8 L Canada 8.8 L Canada
8.8L collected per 1,000 population
(2017 data)
… but has one of the lowest plasma donation rates
• Few source plasma (apheresis) collection centers have been established (non-remunerated model)
primarily from recovered plasma
(for which no alternative exists)
Sources: Bédard, J.P. (2020) "Navigating Complexity: Ensuring Security of Supply." Canadian Blood Services, Jaworski, P. (2020) "Bloody Well Pay Them: The Case for Voluntary Remunerated Plasma." Adam Smith Research Trust, Medical Research Bureau, Canada 2019/20. Calculation from 'Protecting Access to Immune Globulins for Canadians – Final Report of the Expert Panel. Health Canada. 2018.
Sudbury's center is the first of three new Canadian Blood Services dedicated plasma-donor centers that are opening across Canada. First announced in August 2019, these donor centers represent a proofof-concept approach aimed at offering an optimized collections model that leverages Canadian Blood Services' extensive expertise and industry best practices for plasma collection.
Media Release December 16, 2020
"Through a unique consultative partnership, we have had the opportunity to learn from the best practices Grifols has refined to improve and streamline our plasma collections in our new plasma donor centres. As the national blood authority, Canadian Blood Services will continue to deliver on our mandate to support patients by operating the national blood system guided by the principles outlined by Justice Horace Krever." Jean-Paul Bédard, Vice-President Plasma Operations, Canadian Blood Services
"Grifols, with more than three decades providing trusted plasma medicines to Canadians, is extremely pleased to deepen its relationship with Canadian Blood Services to expand Canada's plasma-collection infrastructure to meet the growing demand for plasma therapies and enhance the health and quality of life of the Canadian patients who depend on them."
Joel Abelson, President Grifols' Bioscience Commercial Division
Investor & Analyst Day June 21
| Grifols' is committed to helping countries reach self sufficiency of plasma derived medicines |
For 30+ years, Grifols has been the primary fractionator of Canadian plasma under contract manufacturing services |
Strengthening Grifols' presence in Canada, building on a legacy of partnership in Canada's blood system |
|---|---|---|
| Market opportunity as demand continues to grow and IG use per capita is one of the highest in the world |
Only large-scale domestic manufacturing facility |
Uniquely positioned for continued growth across full platform of service offerings |
Investor & Analyst Day June 21
Alfredo Arroyo – Chief Financial Officer
- 172 -
Investor & Analyst Day June 21
1
- 173 -
Investor & Analyst Day June 21
2020 IAD Key Takeaways
| Driving long-term sustainable growth across all divisions |
Reinforcing our international expansion through SRAAS in China and alliances in Canada and Egypt |
Increasing plasma supply through organic and inorganic initiatives |
|---|---|---|
| Integrated innovation efforts as a core strategic pillar |
Continuous CAPEX to support future growth |
Deleveraging and securing liquidity remain key priorities |
- 174 -
Investor & Analyst Day June 21
2020 IAD Key Takeaways
Investor & Analyst Day June 21
- 176 -
- 177 -
Analyst Day June 21
Investor & Proven Resilience During Unprecedented Times
2021 COVID Impacts
+ -
Larger contribution from SRAAS
Bioscience topline performance impacted by lower plasma collections
- 178 -
Investor & Analyst Day June 21
- 179 -
Analyst Day June 21
Structural costs optimization plan
Divest non-strategic business lines
Resetting Cost Base to Promote Innovation
6 Strategic Investments Led to a Higher Leverage Ratio
2021 Investor & Analyst Day June 21
Debt and leverage ratio remain a key priority
Efforts to reduce debt without missing strategic opportunities
Securing liquidity
Investor & Analyst Day June 21
- 183 -
Demonstrated Ability to Successfully Expand
- 184 -
2021
Analyst Day June 21
Investor & Analyst Day June 21
Consolidating Our Competitive Advantage
Q4 2020 Acquisition of 11 plasma centers from Green Cross
Q1 2021 Acquisition of 25 plasma centers from BPL
Q2 2021 Acquisition of 7 plasma centers from Kedrion
• 7 U.S.-based plasma centers that obtain 240k liters of plasma/year
• USD 55 million
Q1 2021 Plasma Supply Agreement in Hungary
• 7 Hungary-based plasma centers that obtain 120k liters of plasma/year
Integrating Alkahest and GigaGen
Acquisition of the remaining 55% equity of GigaGen
September 7, 2020 March 9, 2021
Acquisition of the remaining 56% stake of GigaGen
Canada, Egypt and China Lead the Way
October 1, 2020 Closing of the acquisition of Green Cross fractionation plant in Canada
November 24, 2020
• The plasma centers will initially collect around 600k liters plasma/year. The plant will have a fractionation capacity of up to 1m liters/year
P&L Variations
- 188 -
1
Investor & Analyst Day June 21
Clear focus on ESG and integrated reporting Further promote our transparency on ESG-oriented initiatives Recognized among the world's most sustainable companies: DJSI, Euronext Vigeo, FTSE4Good, Bloomberg Gender Equality Index and S&P Global Ratings Fluid and transparent communications are crucial, especially during these unprecedented times Grifols is intensifying its efforts to maintain a reinforced constant dialogue with stakeholders In light of the recently issued norm by the Spanish Law and embraced by the Spanish Stock Exchange (CNMV) and the fact that Grifols' performance is not quarterly driven, the company will henceforth release its earnings results on a half year basis ESG Fluid and Transparent Communications Earnings Releases
| Streamlined focus on value creation fundamentals |
Active efforts to divest non-strategic line of businesses |
Increasing profitability through driving innovation |
|---|---|---|
| Deleveraging and liquidity remain a key priority |
Successful track record of organic and inorganic growth |
Clear focus on ESG and integrated reporting Half Year earnings release |
Investor & Analyst Day June 21
- 191 -
Thomas Glanzmann – Vice-Chairman of Grifols' Board of Directors and Chairman of Grifols' Sustainability Committee Nuria Pascual – VP Corporate Treasury & Investor Relations Officer
Investor & Analyst Day June 21
1
- 192 -
Investor & Analyst Day June 21
Built Historically on Our Strong Corporate Values
Commitment Based on Ethical Leadership and Internationally Recognized
On the Path Towards 2030 and Beyond Led by Our 4 Pillars
Investor & Analyst Day June 21
- 196 -
Investor & Analyst Day June 21
- 197 -
Our Commitment Promotes Equality, Diversity, Inclusion and Development
Equal Opportunities, Diversity and Professional Development
- 199 -
Ensuring Non-Discrimination and Donor Health, Safety and Well-Being
Grifols' Commitment to Patients is Based on Three Pillars
- 201 -
Analyst Day June 21
Our Sustainable Business Model Pursues Social Value
(1) Corresponds to the high end of the sensitivity analysis performed
Day
Investor & Analyst June 21 Social Action Plan
Education
Help promote access to education and equality of opportunities in communities where Grifols operates
Contribute to driving positive change: gender equality, ethics and values
Build close ties in donor communities and areas where production facilities are located
Community programs in other countries and humanitarian aid
Promote and improve access to healthcare
Promote science as a driver of positive change
Contribute to recover and enhance natural and environmental patrimony
Direct initiatives and joint projects in collaboration with nature conservation associations
- 204 -
Our Six Commitments for 2030
- 205 -
| Since our beginnings in 1909, we have continually strengthened our commitment to generate social impact |
Our commitment promotes equality, diversity, inclusion and talent development |
Non-discrimination and measures to ensure donors' health, safety and well-being |
|---|---|---|
| Supporting patients through access to treatment, awareness campaigns and support programs |
Creating social value beyond financial performance |
Significant progress on 2030 environmental targets |
Investor & Analyst Day June 21
Víctor Grífols Deu – Co-CEO
- 207 -
Since 2005, We Have Excelled in 3 Core Pillars Leading to a 10 Fold Growth
- 208 -
Emerging Stronger From the Pandemic; Results to Start Paying Off in the Short-term
1 10 of 20 centers to be opened during 2021; 2. Total DCs opened from 2020 Q4 until end of 2021
- 209 -
Investor & Analyst Day June 21
Collecting Results From New Innovation Approach While Paving the Way for the Future
New Scientific Innovation Organization
Expand towards a holistic approach in our core therapeutic areas (Internal, External, Plasma, Non-plasma)
- 210 -
2021
Analyst Day June 21 A Global Ecosystem to Deliver Value in Our Core Therapeutic Areas
- 211 -
Revenue
- 212 -
2021
Analyst Day June 21
- 213 -
June 3, 2021
Investor & Analyst Day June 21
- 215 -
2021 Investor & Analyst Day June 21
- 216 -
2021 Investor & Analyst Day June 21
- 217 -
- 219 -
Day June 21
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.